Work

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

Year: 2013

Type: article

Abstract: The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.42.9829

Authors: Geoffrey R. Oxnard, Adam Binder, Pasi A. Jänne

Institutions: Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute